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Abstract
 Background—Real-world comparative benefits and risks of infliximab (IFX) and adalimumab 
(ADA) in patients with ulcerative colitis (UC) is unclear.
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 Aims—To evaluate the comparative effectiveness and safety of IFX and ADA in patients with 
UC who were new users of anti-TNF agents.
 Methods—Using an administrative claims database (Optum Labs Data Warehouse), we 
identified patients who received first anti-TNF (IFX, ADA) prescription after a 12-month period 
without any anti-TNF treatment (baseline), and with a minimum 6-month follow-up after anti-TNF 
initiation. Primary outcome measures were: all-cause and UC-related hospitalization, abdominal 
surgery, corticosteroid use >60 days after starting anti-TNF, and serious infections. We performed 
2:1 propensity-score matched Cox proportional hazard analysis, and inverse probability-of-
treatment weight (IPTW) analysis, accounting for healthcare utilization, comorbidities and use of 
UC-related medication.
 Results—We included 1,400 new users of anti-TNF agents (age, 43±15 years; 52% males), 
from 2006-14. On propensity-score matched analysis, there was no significant difference in the 
risk of UC-related hospitalization (IFX vs. ADA; adjusted hazard ratio [aHR], 1.04; 95% 
confidence interval [CI], 0.71-1.51), corticosteroid use (aHR, 0.85; 95% CI, 0.68-1.06) and serious 
infections (aHR, 0.62; 95% CI, 0.29-1.34) between IFX- and ADA-treated patients; the number of 
surgical events was very small. On IPTW analysis, risk of corticosteroid use was significantly 
lower in IFX- as compared to ADA-treated patients (aHR, 0.82; 95% CI, 0.68-0.99). Results were 
stable on multiple sensitivity analyses.
 Conclusion—In a large retrospective cohort of patients with UC who were new users of anti-
TNF agents, IFX-treated patients may have lower corticosteroid use than ADA-treated patients, 
but risk of hospitalization and serious infections was comparable.
Keywords
Biologics; outcomes; real-world effectiveness; administrative database; comparative; propensity 
matching
 Introduction
Biologic therapy with anti-tumor necrosis factor-α (anti-TNF) agents such as infliximab 
(IFX) and adalimumab (ADA), alone or in combination with immunomodulators, is one of 
the most effective treatments in inducing and maintaining clinical remission in patients with 
ulcerative colitis (UC), and has been shown to decrease risk of hospitalization and surgery.1 
In the absence of head-to-head trials, there is a unmet need among patients and clinicians to 
better understand the relative effectiveness and safety of different anti-TNF medications. 
Current decisions on the choice of anti-TNF agent are primarily driven by insurance 
coverage and patient and clinician preferences; however, there are differences in the 
molecular construct, dosing and route of administration of these agents; hence, there may be 
differences in effectiveness.2
Therefore, we sought to study the real-world comparative effectiveness and safety of 
different anti-TNF agents in adult patients with UC who were new users of anti-TNF agents, 
using a propensity-score matched retrospective cohort study, in a nationally representative 
administrative database of privately insured individuals derived from the Optum Labs Data 
Warehouse.3 Using patient-important outcomes of all-cause and UC-related hospitalizations, 
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abdominal surgery, need for corticosteroids, and risk of serious infections, the results of this 
study might assist consumers, clinicians, purchasers, and policy makers to make informed 




We conducted a retrospective analysis of medical and pharmacy administrative claims from 
a large database, Optum Labs Data Warehouse, which includes privately insured and 
Medicare Advantage enrollees throughout the United States.3 The database contains data on 
more than 100 million enrollees, from geographically diverse regions across the United 
States, with greatest representation from the South and Midwest. Medical claims include 
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) 
diagnosis codes; ICD-9 procedure codes; Current Procedural Terminology, Fourth Edition 
(CPT-4) procedure codes; Healthcare Common Procedure Coding System (HCPCS) 
procedure codes; site of service codes; and provider specialty codes. All study data were 
accessed using techniques compliant with the Health Insurance Portability and 
Accountability Act of 1996, and because this study involved analysis of preexisting de-
identified data, it was exempted from institutional review board approval.
 Study Population
We identified all patients who filled a prescription for IFX or ADA or received an infusion 
for an anti-TNF agent in the clinic setting between January 1, 2006 and June 30, 2014. Our 
study cohort comprised of adult patients (≥18 years) with: (a) at least one ICD-9 diagnosis 
code of UC (ICD 556.x) in the baseline period (prior to index date of anti-TNF prescription), 
either from an inpatient or outpatient visit, (b) continuous health plan enrollment with 
pharmacy benefits, with no anti-TNF prescription in the 12 months prior to index date (to 
identify a group of anti-TNF-naïve patients), and at least a 6-month minimum enrollment in 
health plan after index date (patients who received anti-TNFs for <6m, and discontinued due 
to intolerance or primary non-response, but still remained in the health plan were included 
and considered treatment failures). These new users of anti-TNF agents were considered 
biologic-naïve since they had not received a prior prescription of an anti-TNF agent in the 
preceding 12m. We excluded patients with a concomitant diagnosis of rheumatoid arthritis, 
ankylosing spondylitis, psoriasis or psoriatic arthritis within the previous 12 months of anti-
TNF prescription date, as competing causes for prescribing anti-TNF agents. In case a 
patient received diagnostic codes for both UC and Crohn's disease, then the patient was 
classified as having UC if the majority of last nine diagnostic codes were for UC.4 
Golimumab was not approved in the United States for commercial use in moderate to severe 
ulcerative colitis until May 2013; therefore, we did not have sufficient data on the use of this 
anti-TNF agent in our cohort. Figure 1 shows the flow of patients for identification of the 
cohort, and Supplementary Figure 1 outlines the general study scheme.
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 Exposures and Outcomes of Interest
The primary exposures of interest were prescription of IFX or ADA for UC. We considered 
patients as being continuously exposed from the index date (date of first prescription of anti-
TNF agent) for the duration of their prescription. Patients were followed until occurrence of 
the outcome of interest (see below), disenrollment from healthcare plan, treatment 
discontinuation or switching (absence of new prescription for a period of >4 months [for 
IFX] or >3 months [for ADA], either discontinuing all anti-TNF agent use or switching to 
another anti-TNF agent), or completion of the study (last date of follow-up, December 31, 
2014).
The primary outcomes of interest were:
 Effectiveness Outcomes
a. All-cause hospitalization
b. UC-related hospitalization, with UC either as the primary diagnosis, or as a 
secondary diagnosis if the primary diagnosis was related to a gastrointestinal 
symptom (abdominal pain, diarrhea, nausea, vomiting, constipation, 
gastrointestinal bleeding)
c. Colectomy (identified using established procedural codes)5
d. Corticosteroid prescription, occurring at least 60 days after the start of anti-
TNF therapy (to minimize confounding by disease severity)
e. Persistence on the index anti-TNF agent at 6-months (prescription of index 
anti-TNF agent between 140-220 days after index date)6 and 12-months 
(prescription of index anti-TNF agent between 325-405 days after index date)
 Safety Outcomes
f Hospitalization for serious or opportunistic infections as primary diagnosis 
(Supplementary Appendix).7
If the index anti-TNF agent was started during an inpatient hospitalization, then that 
hospitalization was not counted as an outcome; only inpatient admissions occurring >23 
hours after drug initiation were regarded as outcomes (to avoid misclassifying observation 
visits for IFX infusions as outcome).
 Covariates of Interest
Independent variables of interest included measures of healthcare utilization, comorbidities 
including surrogate markers of disease severity, and overall medication burden, including 
use of IBD-related medications, in the baseline period (prior to initiation of the index anti-
TNF agent). We assessed baseline healthcare utilization based on the number of all-cause 
hospitalizations, outpatient and emergency department visits, number of endoscopic 
procedures (upper endoscopy, colonoscopy, sigmoidoscopy, capsule endoscopy) identified 
via CPT codes, number of abdominal/pelvic radiologic procedures (magnetic resonance 
imaging, computed tomography, small bowel follow-through, barium enemas) and number 
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of different medication classes filled, both in the preceding 3 and 12 months. Comorbidity 
burden was measured using the validated Charlson–Deyo comorbidity index for 
administrative data.8 While we did not have access to individual participant data medical 
records, endoscopy reports or biochemical parameters, we evaluated surrogate markers of 
disease severity, based on diagnostic codes for weight loss, malnutrition and anemia. 
Medication burden was assessed using overall generic and specific medication class count. 
We also evaluated UC-related medication use in the baseline 3- and 12-months including use 
of 5-aminosalicylates (mesalamine, sulfasalazine, balsalazide, olsalazine), oral 
corticosteroids (prednisone, budesonide), immunomodulators (azathioprine, 6-
mercaptopurine, methotrexate), other immunosuppressive medications (tacrolimus, 
cyclosporine, mycophenolate mofetil), and use of narcotic pain medications.
Patients were classified as being on anti-TNF-based combination immunomodulator therapy 
if they received immunomodulator prescriptions within 30 days before and/or after anti-TNF 
index start date. Based on corticosteroid use, patients were classified as: (a) remote users (if 
they received prescriptions for corticosteroids in the preceding 90 to 365 prior to index anti-
TNF start date, but not within 90 days prior to start of anti-TNF), and (b) recent users (if 
they received prescriptions for corticosteroids in the preceding 90 days prior to index anti-
TNF start date).6
 Statistical Analysis
We examined the relative effectiveness of IFX and ADA on the risk of all-cause and UC-
related hospitalization, abdominal surgery, corticosteroid use and serious infections, using 
two statistical approaches. First, our primary analysis was performed using 2:1 propensity 
score matching without replacement to adjust for differences in baseline covariates, 
comparing patients exposed to IFX vs. ADA.9 The propensity score model included 
demographic variables (age categories, sex, census region), date of initiation of index anti-
TNF, comorbidity index, healthcare utilization (as described above), surrogate markers of 
disease severity, medication class count, and IBD-related medications. We performed a 
paired t-test for continuous variables, a McNemar test for dichotomous variables, and a 
Bowker's test for categorical variables with more than two levels; then, we measured the 
standardized difference of each covariate in the propensity score model, and variables were 
considered to be different across treatment if after propensity score matching the 
standardized difference was greater than 10%. In order to correct for any remaining 
imbalance after the propensity score analysis was performed, we included remaining 
covariates that were shown to be different across treatment groups into the final multivariate 
Cox proportional hazard models for assessment of the outcomes of interest. Second, we 
performed an inverse probability-of-treatment weight (IPTW) analysis where the IPTW was 
applied to each observation in the Cox model in order to assess the relative effectiveness of 
IFX and ADA. The IPTW analysis was derived by utilizing the propensity score on all 
observations before matching.10 In contrast to propensity-score matching in which the 
sample size decreases, this type of modeling allowed us to retain all identified patients in the 
analysis and increased power.
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We calculated hazard ratios (HR) with 95% confidence intervals (CI) for each outcome of 
interest separately, and patients were censored at time of treatment discontinuation or 
switching (to another anti-TNF agent), health plan disenrollment or end of observation 
period. We created the analytic dataset in SAS 9.3 and used Stata SE software (version 13.0) 
for statistical analysis.
 Sensitivity Analysis
We performed multiple sensitivity analyses to assess the robustness of our findings. First, to 
minimize the risk of being misclassified as anti-TNF-naïve, we analyzed only patients with 
at least 2- and 3-year baseline anti-TNF-free period in our cohort (i.e., no anti-TNF 
prescriptions for at least 2 or 3 years prior to start date of index anti-TNF agent). Second, 
because inpatient biologic use is not consistently captured by inpatient claims, we excluded 
patients who had an inpatient hospitalization within 30 days prior to the observed initiation 
of anti-TNF agents to minimize confounding by disease severity and misclassifying non-
responders. Third, since ADA was approved by the US Food and Drug Administration 
(FDA) in 2012, we excluded patients with UC who's anti-TNF initiation date was before 
2012, limiting only to patients started on anti-TNF agent between 2012-14. We also 
performed stratified analysis based on use of anti-TNF monotherapy or combination therapy 
(concomitant use of immunomodulators).
 Results
 Characteristics of Patients
We identified 1400 patients with UC who started on their first anti-TNF agent between 2006 
and 2014 and who had at least 18 months' continuous enrollment in the health plan (12 
months prior to start of anti-TNF agent, and 6 months after initiating index anti-TNF agent). 
Of these, 1112 were treated with IFX, and 288 were treated with ADA as the index anti-TNF 
agent; on limiting only to patients with initiation date of index anti-TNF agent after 2012, 
308 were treated with IFX and 171 were treated with ADA. Table 1 describes the baseline 
demographic, clinical, treatment characteristics and healthcare utilization of the overall 
cohort and the three subgroups. Median follow-up (and interquartile range [IQR]) after 
starting index anti-TNF agent was 19 months (IQR, 10-35), with significantly longer follow-
up in IFX-treated patients as compared to ADA-treated patients (p<0.001). Only 9.4% of 
patients were >65 years old. Overall, the groups were comparable with regard to 
demographic and clinical variables, as well as healthcare utilization in the baseline period, 
except significantly higher rates of hospitalization in the 12 month prior to starting anti-TNF 
in IFX-treated patients (40%) than ADA-treated patients (30%) (p<0.001)
The patients were also comparable with regard to baseline UC-related medication use. 
About 82% of patients received corticosteroids anytime in the 12-month baseline period, 
with a median of 3 prescriptions (IQR, 1-5); ADA-treated (86%) patients were more likely 
to have received corticosteroids compared to IFX-treated (81%) patients. However, there 
was no significant difference in the proportion of patients receiving corticosteroids in the 90 
days prior to initiation of anti-TNF agent (total, 66%). Approximately 55% patients received 
a prescription of immunomodulator or immunosuppressive therapy in the 1 year prior to 
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index agent, with no difference across groups. The proportion of patients on anti-TNF-based 
combination therapy (immunomodulator prescriptions within 30 days before and/or after 
anti-TNF index start date) was comparable between groups (IFX vs. ADA: 33% vs. 32; 
p=0.71). Approximately 42% patients received narcotics in the preceding year, with 
comparable rates between IFX- and ADA-treated patients.
After propensity score matching, these groups were more balanced, with no significant 
difference in clinical variables, healthcare utilization or UC-related medication use 
(Supplementary Table 1). Only a small number of variables fell outside a standardized 
difference of 0.10 (Supplementary Figure 2); these variables were additionally adjusted for 
in the propensity score-matched multivariable Cox proportional hazard analysis.
 Comparative effectiveness and safety of infliximab vs. adalimumab – Propensity 
Matched Analysis
A total of 544 patients treated with IFX were propensity score-matched to 272 ADA-treated 
patients. On unadjusted analysis, the risk of all-cause hospitalization and corticosteroid 
prescription was lower in IFX-treated patients compared to ADA-treated patients (Figure 
2A-D). On Cox proportional hazard analysis, after additional adjustment for variables not 
balanced through propensity score matching, we observed that the risks of all-cause (aHR, 
1.05; 95% CI, 0.78-1.43) and UC-related hospitalization (aHR, 1.04; 95% CI, 0.71-1.51), 
corticosteroid use > 60 days after initiation of anti-TNF therapy (aHR, 0.85; 95% CI, 
0.68-1.06) and risk of serious infections (aHR, 0.62; 95% CI, 0.29-1.34) was not 
significantly different between IFX- and ADA-treated patients (Table 2). The number of 
surgical events was very small, precluding meaningful analysis. Persistence on index anti-
TNF was comparable for IFX and ADA at 6-months (IFX vs. ADA, 79% vs. 74%, p=0.08), 
but significantly higher for IFX at 12-months (57% vs. 42%, p<0.001); after adjusting for 
variables that were unbalanced after propensity score matching, the probability of 
persistence on IFX and ADA at 6-months was 78% and 75%, respectively (p<0.001), and 
the corresponding rates at 12-months were 54% and 47%, respectively (p<0.001).
The overall results were similar on stratified analysis by anti-TNF monotherapy or 
concomitant immunomodulator therapy (Table 3). The results were also similar to the 
primary analysis on sensitivity analysis restricting only to (a) patients with at least a 3-year 
baseline anti-TNF-free period (Table 2), and (b) patients without inpatient hospitalization 
within 30 days prior to initiation of anti-TNF agents (Supplementary Table 2), and (c) 
patients with index date after 2012 (Table 4).
 Comparative effectiveness and safety of infliximab vs. adalimumab – Inverse Probability-
of-Treatment Weight Analysis
The overall results were largely comparable to the primary propensity-score matched 
analysis, when using IPTW analysis. There were no significant differences in the risks of all-
cause and UC-related hospitalization or risk of serious infections between IFX- and ADA-
treated patients (Table 2). However, the need for corticosteroids any time after initiation of 
index anti-TNF agent (aHR, 0.83; 95% CI, 0.69-1.00) and >60 days after anti-TNF initiation 
(aHR, 0.82; 95% CI, 0.68-0.99) was significantly lower in IFX-treated patients as compared 
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to ADA-treated patients. The adjusted probability of persistence on IFX and ADA at 6-
months was 78% and 72%, respectively (p<0.001), and the corresponding rates at 12-months 
were 54% and 41%, respectively (p<0.001).
The overall IPTW results were similar on stratified analysis by anti-TNF monotherapy or 
concomitant immunomodulator therapy (Table 3). The results were also similar to the 
primary IPTW analysis on sensitivity analysis restricting only to (a) patients with at least a 
3-year baseline anti-TNF-free period (Table 2), (b) patients without inpatient hospitalization 
within 30 days prior to initiation of anti-TNF agents (Supplementary Table 2), and (c) 
patients with index date after 2012 (Table 4).
 Discussion
While anti-TNF-based therapy is one of the most effective treatments for UC, there are 
limited data on the comparative effectiveness and safety of different anti-TNF agents. In this 
nationally representative, propensity score-matched retrospective cohort study of 1,400 
patients with UC who were new users of anti-TNF agents, we made several key 
observations. First, we observed that there were no significant differences in the risk of all-
cause or UC-related hospitalization after starting IFX or ADA as the first anti-TNF agent; 
the number of surgical events was small precluding meaningful analysis. Second, we 
observed that there was IFX-treated patients may have lower need for corticosteroids (after 
starting index anti-TNF agent) as compared to ADA-treated patients, using IPTW analysis, 
although this was not statistically significant in the propensity-matched analysis. Third, 
there was no significant difference in the risk of serious infections requiring hospitalization 
among IFX- and ADA-treated patients, although there was a consistent but non-significant 
trend for fewer serious infections among the IFX-treated patients. Based on the findings of 
our observational study, IFX and ADA appear comparable for most key patient-related 
effectiveness and safety outcomes for treatment of UC, although IFX-treated patients may be 
less likely to require corticosteroids and are likely to stay on their index anti-TNF longer. 
This is one of the largest observational comparative effectiveness studies in a contemporary 
cohort of UC patients, with patient-important effectiveness and safety outcomes, assessed 
with robust complementary statistical approaches, with several stratified and/or sensitivity 
analyses.
These results were consistent on sensitivity analysis after (a) excluding patients with 
inpatient hospitalization in the preceding 30 days (to minimize misclassification of non-
responders and confounding by disease severity), (b) on restricting analysis to patients with 
at least a 3-year baseline anti-TNF-free period (to minimize misclassification of anti-TNF-
naivety), and (c) on restricting only patients started on anti-TNF agent after 2012 (after US-
FDA approval of ADA). The results were also similar on analysis stratified by use of anti-
TNF monotherapy and combination immunomodulator therapy, with comparable summary 
estimates.
Indirect treatment comparison network meta-analyses have suggested that in a subset of 
biologic-naïve patients with UC, IFX may be superior to ADA for induction of clinical 
response and mucosal healing,11, 12 but comparable for maintenance of remission.13 
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However, there are subtle differences in trial designs and co-interventions, with no head-to-
head trials, which decreases the quality of evidence from these network meta-analyses. 
Moreover, all of these trials had restrictive inclusion criteria and were short-term (maximum 
maintenance therapy, 1 year), and hence, not representative of real-world patient-important 
outcomes.
There have been a limited number of observational studies on the comparative effectiveness 
of different anti-TNF agents in IBD. In a retrospective multi-site cohort study in which 170 
physicians reported on 6-month outcomes of biologic-naïve IFX- (n=380) or ADA-treated 
(n=424) UC patients from their practices, there were no significant differences in clinical 
response (based on physician global assessment), healthcare utilization and partial Mayo 
score between the two groups, similar to our findings.14
In our study, there were subtle differences in the results depending on choice of the 
statistical approach, particularly for one of the outcomes (need for corticosteroids). 
Propensity-score matching resulted in loss of sample size, such that we included only 816 
out of 1400 eligible patients. IPTW analysis, on the other hand, allowed us to overcome this 
limitation and include all 1400 patients in the analysis, increasing statistical power to detect 
small differences. In the IPTW analysis (but not the propensity score-matched analysis), we 
observed a lower risk of steroid requirement in IFX-treated patients compared to those 
treated with ADA, However, no significant differences were observed in the propensity-
score matched and IPTW analysis for other outcomes.
Our findings must be interpreted with caution, given the limitations associated with our 
study design. First, this was an observational, not an interventional study, and hence, there 
may be unmeasured confounders across groups. The potential for unmeasured confounding 
by severity is of particular importance, as administrative data do not include objective 
measures of disease severity such as endoscopic or biochemical markers; patients with acute 
severe colitis were excluded. Anecdotally, in our clinical practice, patients with more severe 
disease may preferentially be recommended IFX over ADA. This may bias results against 
IFX, since sicker patients (at highest risk of patient-important outcomes) may be more likely 
to be given IFX. We also did not have data on baseline cigarette smoking status and body 
weight, both of which can influence outcomes; however, there is no clear reason why 
tobacco use would be different across exposure groups. Second, there is potential for 
misclassification of patients as new users of anti-TNF agents, since the baseline period 
required that patients not have received another anti-TNF agent only 1 year prior to index 
date. It is well known that the response to a second anti-TNF agent is generally inferior to 
that of the first anti-TNF agent, and likewise, response decreases for the 3rd anti-TNF agent 
as compared to the second.15 However, on sensitivity analysis increasing the baseline period 
to 3 years, we observed similar summary estimates for patient-important outcomes, 
supporting the robustness of our findings. Additionally, on restricting to a subset of patients 
who received their index anti-TNF agent after 2012 (after FDA approval of ADA for UC), 
we observed similar results. We were unable to account for the impact of therapeutic drug 
monitoring or dose escalation, practices which have become more common recently, given 
inaccurate estimation using administrative databases. However, results were similar when 
restricted to 2012 onwards, and this would capture recent practices in UC management. 
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Third, both baseline covariates and outcomes were measured using administrative claims 
codes and may be subject to errors. Definitions for some covariates and outcomes, such as 
combination immunosuppressive therapy, treatment discontinuation, etc. were chosen using 
best investigator judgment, and have not been validated. The number of surgical events and 
serious infections was small, precluding meaningful analysis; the incidence of serious 
infections was low and hence, this analysis may have been underpowered. Fourth, by 
restricting inclusion only to patients with at least 6-month follow-up in the same healthcare 
plan after initiation of anti-TNF agents (regardless of whether they continued on medication 
or not), we may have potentially missed some patients with poor response to induction 
therapy and left the plan before 6 months. There may have been early mortality, a vital 
outcome that was missed; however, mortality is very uncommon in patients with UC. By 
choosing a 6-month cut-off, we were able to ensure a more homogenous cohort for accurate 
estimation of outcomes. Finally, the possibility of observing statistically significant results 
may be related to chance due to multiple statistical testing for related outcomes.
In conclusion, using a propensity-matched retrospective observational cohort study, we 
observed that IFX and ADA may be comparable for key patient-important outcomes such as 
risk of hospitalization and serious infections, in patients with UC who were new users of 
anti-TNF agents; the risk of surgery was low in both cohorts. The need for corticosteroids 
may be modestly lower, and persistence on index anti-TNF agent higher, in IFX-treated 
patients as compared to ADA-treated patients with UC. Future prospective cohort studies 
with adjustment for baseline objective measures of disease severity and pragmatic 
randomized controlled trials are warranted to confirm these observations.
 Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Flow of patients for identification of the ulcerative colitis cohort who were new users of anti-
TNF agents.
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Survival free of (a) all-cause hospitalization, (b) UC-related hospitalization, (c) 
corticosteroid prescription (at least 60 days after index anti-TNF agent) and (d) 
hospitalization for serious infection, in comparing propensity-score matched cohort of 
patients treated with infliximab vs. adalimumab as first-line index anti-TNF agent. IP refers 
to inpatient hospitalization.
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Table 1
Baseline demographic characteristics, healthcare utilization and IBD-related medication use in the 12 months 








Mean age ± SD, years 43 ± 16 42 ± 14 0.14
Sex (% males) 52 52 1.00





Healthcare utilization (in 12 months prior to starting anti-TNF)
Median outpatient visits (IQR) 9 (5-13) 9 (6-14) 0.22
Emergency room visits (% pts with ≥1) 41 41 0.81
Inpatient visits (% pts with ≥1) 40 30 <0.001
Imaging (% of pts with ≥1) 24 26 0.49
Endoscopic procedures (% pts with ≥1) 76 76 0.91
Median generic medication count (IQR) 6 (4-9) 6 (4-9) 0.91
IBD-related medication use (in 12 months prior to starting anti-TNF)
Mesalamine, oral, % 77 81 0.16
Steroids
• Any prior use, % 81 86 0.04
• Recent (in 90 days prior to anti-TNF), % 66 68 0.35
Immunomodulators
• Any prior use, % 51 46 0.14
• Concurrent (index date ± 30 days), % 33 32 0.71
Narcotics, % 41 45 0.22
[Abbreviations: IQR-interquartile range, n-number of patients, pts-patients, SD-standard deviation, TNF-tumor necrosis factor]



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Singh et al. Page 19
Table 3
Stratified analysis, by baseline use of anti-TNF monotherapy and combination immunomodulator therapy.
Outcomes of interest
Propensity Score Matched Analysis Inverse Probability-of-Treatment Weighted Analysis
HR (95% CI), IFX vs. ADA p-value HR (95% CI), IFX vs. ADA p-value
Anti-TNF monotherapy (within ±30 days of index date)
All-cause hospitalization 1.09 (0.77, 1.55) 0.631 0.98 (0.72, 1.34) 0.918
UC-related hospitalization 1.08 (0.70, 1.66) 0.733 1.09 (0.73, 1.63) 0.662
Steroid use (>60 days after anti-TNF 
initiation) 0.88 (0.68, 1.13) 0.312 0.84 (0.66, 1.07) 0.165
Serious infections 0.60 (0.25, 1.41) 0.229 0.72 (0.34, 1.51) 0.382
Anti-TNF combination therapy (within ±30 days of index date)
All-cause hospitalization 0.87 (0.44, 1.71) 0.675 1.04 (0.60, 1.80) 0.918
UC-related hospitalization 0.72 (0.31, 1.69) 0.452 0.88 (0.44, 1.77) 0.715
Steroid use (>60d after anti-TNF initiation) 0.78 (0.49, 1.23) 0.283 0.72 (0.49, 1.04) 0.083
Serious infections 0.69 (0.12, 4.04) 0.685 0.59 (0.13, 2.66) 0.493
[Abbreviations: ADA-adalimumab, CI-confidence interval, IFX-infliximab, TNF-tumor necrosis factor, UC-ulcerative colitis]













Singh et al. Page 20
Table 4
Sensitivity analysis, on restricting only to patients with initiation of index anti-TNF agent 
after 2012 (approval year of ADA for UC)
Comparative effectiveness and safety of infliximab vs. adalimumab in patients with ulcerative colitis who were 
new users of anti-TNF agents (with 1-year baseline anti-TNF-free period), using 2:1 IFX:ADA propensity-
score matched analysis (138 IFX-treated patients vs. 69 ADA-treated patients) and inverse probability-of-
treatment weighted analysis (308 IFX-treated and 171 ADA-treated patients). The number of surgical events 
was very small limiting statistical analysis.
Outcomes of interest
Propensity Score Matched Analysis Inverse Probability-of-Treatment Weighted Analysis
HR (95% CI) (IFX vs. ADA) p-value HR (95% CI) (IFX vs. ADA) p-value
All-cause hospitalization 1.19 (0.67, 2.14) 0.555 0.93 (0.58, 1.47) 0.741
UC-related hospitalization 0.94 (0.46, 1.95) 0.872 0.63 (0.35, 1.12) 0.116
Steroid use (>60 days after anti-TNF 
initiation) 0.81 (0.54, 1.20) 0.286 0.85 (0.62, 1.15) 0.290
Serious infections 0.59 (0.16, 2.17) 0.430 1.07 (0.39, 2.97) 0.892
[Abbreviations: ADA-adalimumab, CI-confidence interval, IFX-infliximab, TNF-tumor necrosis factor, UC-ulcerative colitis]
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